NCT05086666 is a Phase 1, PHASE2 clinical trial of AZD4547 in Urothelial Carcinoma, sponsored by Abbisko Therapeutics Co, Ltd.

Who is sponsoring NCT05086666?

NCT05086666 is sponsored by Abbisko Therapeutics Co, Ltd.

What drugs are being tested in NCT05086666?

Interventions in NCT05086666: AZD4547.

What condition does NCT05086666 study?

NCT05086666 studies Urothelial Carcinoma.

Is NCT05086666 still recruiting?

NCT05086666 is currently status unknown. Last updated 21 October 2021.

Last reviewed 2021-10-21 · How we verify

NCT05086666

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547

Status unknown Phase 1, PHASE2 Last updated 21 October 2021

What this trial tests

Phase 1, PHASE2 trial testing AZD4547 in Urothelial Carcinoma in 108 participants. Status unknown.

Timeline

3 June 2021

Primary endpoint
14 August 2023

27 May 2024

Quick facts

Lead sponsor	Abbisko Therapeutics Co, Ltd
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	108
Start date	3 June 2021
Primary completion	14 August 2023
Estimated completion	27 May 2024
Sites	1 location across China

Drugs / interventions tested

AZD4547 (azd4547) — full drug profile →

Conditions studied

Urothelial Carcinoma — all drugs for Urothelial Carcinoma →

Sponsor

Abbisko Therapeutics Co, Ltd — full company profile →

Who can join

25 and older, any sex, with Urothelial Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase 1b clinical study to evaluate the PK of oral AZD4547 in Chinese patients and RP2D. Phase 2 study to evaluate the efficacy of AZD4547 in urothelial carcinoma patients with FGFR2/3 gene alterations.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Clinically relevant fusion oncogenes: detection and practical implications.
Sorokin M, Rabushko E, Rozenberg JM, Mohammad T, et al · · 2022 · cited 25× · PMID 36601633 · DOI 10.1177/17588359221144108
Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments.
Gordon A, Johnston E, Lau DK, Starling N. · · 2022 · cited 25× · PMID 36238135 · DOI 10.2147/ott.s282718
Fibroblast growth factor receptors as targets for anticancer therapy in cholangiocarcinomas and urothelial carcinomas.
Wekking D, Pretta A, Martella S, D'Agata AP, et al · · 2023 · cited 10× · PMID 37681152 · DOI 10.1016/j.heliyon.2023.e19541
Fibroblast Growth Factor Receptor Inhibitors Decrease Proliferation of Melanoma Cell Lines and Their Activity Is Modulated by Vitamin D.
Piotrowska A, Nowak JI, Wierzbicka JM, Domżalski P, et al · · 2024 · cited 3× · PMID 38473753 · DOI 10.3390/ijms25052505
Scientific advances in drug development and clinical trials for urothelial carcinoma: Highlights from the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium
· 2025

Verify or expand the search:

Other trials of AZD4547

Trials testing the same drug.

NCT05775874 — A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC · Phase 2 · unknown
NCT02546661 — Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer · Phase 1 · active not recruiting
NCT00979134 — Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours · Phase 1 · terminated

Other recruiting trials for Urothelial Carcinoma

Currently open trials in the same condition.

NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors · Phase 1 · recruiting
NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
NCT07421700 — Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer · Phase 1, PHASE2 · recruiting
NCT07492628 — Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma · Phase 1 · recruiting
NCT07390617 — A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma · recruiting

Other Abbisko Therapeutics Co, Ltd trials

Trials by the same sponsor.

NCT07417189 — A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 ) · Phase 1, PHASE2 · recruiting
NCT07297875 — A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia · Phase 1, PHASE2 · not yet recruiting
NCT07164170 — A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib · Phase 2 · not yet recruiting
NCT07210996 — A Study to Evaluate the Relative Bioavailability of Pimicotinib Capsules Containing Free Base in Different Proportions i · Phase 1 · completed
NCT07288957 — A Early Study of ABSK131 in Patients With Advanced/Metastatic Solid Tumors · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05086666 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abbisko Therapeutics Co, Ltd
Last refreshed: 21 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05086666.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing